Categories: News

Taconic Biosciences Appoints Nomura Siam as Distributor in India for All Taconic Animal Models

Improves Access to Critical Rodent Models for Researchers in India

RENSSELAER, N.Y., May 10, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has appointed Nomura Siam International Co., Ltd (NSI), an established distributor of laboratory animals and related products, as its preferred distributor in India.

India makes a significant contribution to global pharmaceutical and vaccine production, and its pharmaceutical and biotechnology research and development is expected to grow over the next decade. To support this growth, scientists in India need advanced mouse and rat models for pharmacology studies and toxicology and drug safety assessment. Research across all therapeutic areas requires genetically engineered models (GEMs). Additionally, mice with humanized immune systems are critical for immuno-oncology and other applications.

Taconic’s portfolio comprises nearly 4,700 mouse and rat models, including widely used standard strains, immunodeficient models, and exclusive GEMs. Taconic is also a global leader in humanized immune system mouse generation. Taconic’s industry-leading quality systems, genetic integrity, and globally harmonized animal health standards promote research reproducibility while its flexible approach to licensing reduces barriers to accessing valuable GEMs.  

Based in Thailand, NSI is known for its focus on quality and customer service. The company’s new agreement with Taconic significantly increases preclinical researchers’ access to GEMs in India and allows NSI to offer this market a full spectrum of solutions.

“To date, rodent model selection and availability has been somewhat limited in India. We believe this partnership will provide India’s growing pharmaceutical industry access to the most sophisticated and high-quality animal models available globally,” said Dr. Michael Seiler, vice president of commercial products at Taconic. “We truly believe this partnership will support Taconic’s desire to accelerate new life-saving therapeutics for the global community.”

“Taconic’s portfolio of sophisticated mouse models fills a major gap in the Indian market,” said Taiichiro Kamiya, president of NSI. “By our frequent information sharing, and the improvement of logistic process, we will provide faster and easier access to GEMs for Indian users.”

To learn more about Taconic’s full line of animal model solutions, please call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates service laboratories and breeding facilities in the US and Europe, maintains distributor relationships in Asia, and has global shipping capabilities to provide animal models almost anywhere in the world.

About Nomura Siam International Co. Ltd. (NSI)

Nomura Siam International Co. Ltd., based in Bangkok, Thailand, was jointly established in 2012 by CLEA Japan, Inc. and Nomura Jimusho, Inc. as a comprehensive provider for the laboratory animal field. As a one-stop service supplier, NSI not only sells laboratory animals but also handles a wide range of related products, including equipment for breeding, conducting experiments, and environmental enrichment, as well as consulting services for preclinical research and laboratory animal facility design.

Media Contact:

Aidan Bouchelle
Associate Director, Marketing Operations
518-949-7598
Aidan.Bouchelle@taconic.com

Staff

Recent Posts

Bemax Announces Financial Results for Fiscal Fourth Quarter Ended May 31, 2024

- Revenue increase of over 600%Dallas, Georgia--(Newsfile Corp. - July 2, 2024) - Bemax Inc.…

2 hours ago

1933 Industries Reports Profit in Q3 2024 Financials

VANCOUVER, BC / ACCESSWIRE / July 2, 2024 / 1933 Industries Inc. (the "Company" or…

2 hours ago

Myriad Genetics Earns 2024 Great Place To Work® Certification™

SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a…

2 hours ago

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

The ceremony will be held in celebration of Scilex’s launch of GLOPERBA®, an innovative non-opioid…

2 hours ago

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG…

2 hours ago